PCI Biotech first quarter 2021 interim results
Oslo (Norway), 7 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2021 results. Please find enclosed the report and presentation.
*Increased screening and enrolment to RELEASE in Q1 after implementation of the amended protocol and the opening of Asian sites. The full effect of these initiatives is not expected until the Covid-19 situation improves further
*The first US patient was enrolled in the RELEASE study in April
*Continued focus on enrolment of patients into the RELEASE study, with the emphasis going forward being on regular trial management, including performance evaluation and replacement of underperforming sites
*The expected timeline for the planned interim analysis remains in the range from 2H 2022 to 1H 2023
*Successful Phase I vaccination proof of concept study published in the high impact immunology journal, Frontiers in Immunology, demonstrating that fimaVacc enhances the immune response to peptide- and protein-based vaccines in healthy volunteers. The focus going forward is utilising the Phase I results in partnering efforts and planning for clinical proof-of-concept in a disease setting
*Encouraging data on enhanced delivery of mRNA for various medical applications was presented at the UK based 12th Annual RNA Therapeutics Virtual Conference in February 2021
*In May 2021, PCI Biotech entered into an extensive research collaboration with the South Korean company OliX Pharmaceuticals, a leading developer of RNAi therapeutics
Per Walday, CEO of PCI Biotech, comments: “We have seen a good increase in patient screening and enrolment into the RELEASE study in Q1 2021, which is encouraging and supports the relevance of our study optimisation efforts. We expect to see the full force of these modifications when the healthcare systems are no longer afflicted by the pandemic. The situation has been difficult in the US, but an increase in activity during Q1 resulted in the first patient being enrolled in April. We are now fully focused on optimal study performance and progress, with the attention to site performance and management of study specific risks. For fimaVacc, we were pleased to see the successful proof-of-concept study published in the high impact immunology journal, Frontiers in Immunology. The focus going forward is utilising these results in partnering efforts and planning for clinical proof-of-concept in a disease setting. We were proud to present the strong collaborative fimaNAc data at a relevant international conference in February. We will be using these results to draw further attention and interest among relevant players within nucleic acid therapeutics. The broad and exciting collaboration recently announced with OliX Pharmaceuticals in South Korea signifies the strengths of our data and we look forward to exploring synergies between our technologies.”
An online presentation in English will be held today, Friday 7 May 2021, at 08.30am CEST (local time). The presentation can be followed as a live webcast, access through link https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20210507_1 or the company’s website under “Investors – Reports and presentations – Webcasts”.
There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The presentation will also be presented through a teleconference, mainly facilitated for investors intending to ask questions verbally during the Q&A session.
Dial-in details for teleconference, mainly facilitated for verbal questions during Q&A session:
If you plan to use this facility, please join the event 5-10 minutes prior to the scheduled start time using the dial-in numbers below. A line mediator will provide information on how to ask questions.
Norway +47 2100 2610 / Sweden +46 (0)8 5033 6574 / Denmark +45 35 15 80 49 / United Kingdom +44 (0)330 336 9105 / United States +1 929-477-0402. If your country is not listed, we recommend that you use the dial-in details for UK.
When prompted, provide the confirmation code or event title.
Confirmation Code: 5592549
Event title: PCI Biotech Q1 2021 Conference Call
The interim report and the presentation will also be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 7 May 2021.
For further information, please contact:
Ronny Skuggedal, CFO
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Klövern ansöker om avnotering av bolagets aktier och utser ny VD24.6.2021 16:18:32 CEST | Pressemelding
Styrelsen i Klövern AB (publ) (”Klövern”) ansöker om avnotering av Klöverns aktier från Nasdaq Stockholm. Eva Landén har utsetts till ny VD för Klövern. Corem Property Group AB (publ) (”Corem”) lämnade den 29 mars 2021 ett offentligt uppköpserbjudande till aktieägarna i Klövern. Corem förklarade erbjudandet ovillkorat den 15 juni 2021. Corem kontrollerar per dagens datum cirka 95,0 procent av de utestående aktierna i Klövern och avser att påkalla tvångsinlösen av resterande aktier. Corem har även förlängt acceptperioden för erbjudandet till och med den 18 augusti 2021. Mot bakgrund av ovanstående, och på begäran av Corem, har styrelsen för Klövern beslutat att ansöka om avnotering av bolagets aktier från Nasdaq Stockholm. Sista dag för handel i Klöverns aktier vid Nasdaq Stockholm kommer att meddelas så snart Klövern erhållit besked om detta från Nasdaq Stockholm. På begäran av Corem har styrelsen i Klövern vidare utsett Eva Landén till ny VD för Klövern. Eva Landén är VD för Corem och
Klövern applies for delisting of the company’s shares and appoints new CEO24.6.2021 16:18:32 CEST | Press release
The Board of Directors of Klövern AB (publ) (”Klövern”) applies for delisting ofKlövern’sshares from Nasdaq Stockholm. Eva Landén has been appointed new CEO of Klövern. On 29 March 2021, Corem Property Group AB (publ) (”Corem”) announced a public offer to the shareholders of Klövern. Corem declared the offer unconditional on 15 June 2021. As of today, Corem controls approximately 95.0 percent of the outstanding shares in Klövern and intends to apply for compulsory redemption of the remaining shares. Corem has also extended the acceptance period för the offer to 18 August 2021. In light of the above, and at the request of Corem, the Board of Directors of Klövern has decided to apply for delisting of the company’s shares from Nasdaq Stockholm. The last day of trading in Klövern's shares will be announced as soon as Klövern has been informed thereof by Nasdaq Stockholm. Further, at the request of Corem, the Board of Directors of Klövern has appointed Eva Landén as new CEO of Klövern. Eva
Lantronix Announces SmartEdge Partner Program Award Winners24.6.2021 13:00:00 CEST | Press release
SmartEdge Partner Program Winners Are Tech Data, SHI, Presidio, Atlantik, Arki, Data Equipment, Acromax, Rahi System India and Enthu Technology Sdn. Bhd. IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM) offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware, today announced the winners of its SmartEdge™ Partner Program Awards. The awards were given at Lantronix’s 2021 SmartEdge Partner Summit held virtually on June 23, 2021. Lantronix’s SmartEdge Partner Program Awards were given to winners in three categories: Distribution Partner, StrategicEdge Partner and Edge Partner covering three regions: North America, Europe/Middle East/Africa and Asia Pacific. The winners are: North America North America Distributor Partner of the Year: Tech Data North America StrategicEdge Partner of the Year
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS24.6.2021 12:05:00 CEST | Press release
Bid procedure, 2021-06-29BondsKOMMUNINVEST I SVERIGE: 2302. SE0009662943. 2023-02-22 KOMMUNINVEST I SVERIGE: 2410, SE0010469205, 2024-10-02 KOMMUNINVEST I SVERIGE: 2602, SE0013745452, 2026-02-04 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2021-06-29Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2302: 500 mln SEK +/-250 mln SEK 2410: 500 mln SEK +/-250 mln SEK 2602: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)2302: 500 mln SEK per bid 2410: 500 mln SEK per bid 2602: 1000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-07-01Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Condition
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER24.6.2021 12:05:00 CEST | Press release
Bid procedure, 2021-06-30CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-12-30 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-06-17 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-06-30Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS24.6.2021 12:05:00 CEST | Press release
Bid procedure, 2021-07-02BondsSWEDISH GOVERNMENT: 1062. SE0013935319. 2031-05-12 SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24 KINGDOM OF SWEDEN: REGS (GREEN), XS2226974504, 2030-09-09 Bid date2021-07-02Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1062: 500 mln SEK +/-250 mln SEK 1063: 500 mln SEK +/-250 mln SEK REGS (GREEN): 250 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1062: 500 mln SEK per bid 1063: 500 mln SEK per bid REGS (GREEN): 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-07-06Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-06-24 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS24.6.2021 12:05:00 CEST | Press release
Bid procedure, 2021-07-01BondsSWEDBANK HYPOTEK AB: 196. SE0015244991. 2026-03-18 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 147, SE0009383664, 2026-06-17 SKANDINAVISKA ENSKILDA: 580, SE0013101722, 2025-12-17 LANSFORSAKRINGAR HYPOTEK: 521, SE0015503446, 2028-09-20 DANSKE HYPOTEK AB: 2212, SE0010297085, 2022-12-21 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2021-07-01Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)196: 400 mln SEK +/-200 mln SEK 1591: 1900 mln SEK +/-950 mln SEK 147: 700 mln SEK +/-350 mln SEK 580: 500 mln SEK +/-250 mln SEK 521: 600 mln SEK +/-300 mln SEK 2212: 500 mln SEK +/-250 mln SEK 5536: 400 mln SEK +/-200 mln SEK Highest permitted bid volume (corresponding nominal amount)196: 400 mln SEK per bid 1591: 1900 mln SEK per bid 147: 700 mln SEK per bid 580: 500 mln SEK per bid 521: 600 mln SEK per bid 2212: 500 mln SEK per bid 5536: 400 mln SEK per bid Lowest permitted bid volume (co